Moderna shares touch all-time high as Phase III plans for COVID-19 vaccine take shape

A clearer picture of the late-stage clinical development path for one of the most advanced COVID-19 vaccines is taking shape as Moderna shares additional details of its Phase III trial design for mRNA-1273.

The main goal for the Phase III COVE trial, which is set to launch on July 27, is to prevent symptomatic disease with SARS-CoV-2, rather than all infections...